Exploratory analysis performed in these studies suggests that overexpression of PD-L2 by AML blasts and monocyte-restricted increase in PD-L1 expression with therapy are potential reasons behind the lack of clinical activity of PD-L1 inhibitors in AML [57,58]. This evidence concerns the gene PDCD1LG2 and acute myeloid leukemia.